Hi Wallymo. Merck is keenly aware that statins induce CoQ10 depletion, and therefore in turn "can cause an increase in cardiac dysfunction," which "can be life-threatening." In fact, Merck holds the patent for CoQ10 to be coadministered with their statin, Mevacor. And yet, some fifteen years later they continue to negligiently sit on this patent -- I suppose in an attempt to eventually corner the market in a combination CoQ10/statin drug.
+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=
United State Patent: 5,082,650
Title: Amelioration of reductions of coenzyme Q.sub.10 in cardiomyopathy patients receiving lovastatin
Inventors: Folkers; Karl A. (Austin, TX), Langsjoen; Per H. (Temple, TX)
*http://patft1.uspto.gov:80/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5082650.PN.&OS=PN/5082650&RS=PN/5082650
Abstract: The present invention comprises the serious side effect of mevinolin to depress body levels of coenzyme Q.sub.10 and to correspondingly depress cardiac function and the circumvention of this side effect by the clinical administration of a formulation of coenzyme Q.sub.10 concommitantly with the administration of the mevinolin.
+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=+=
Again, these are quotes directly from the US patent itself, and fairly inarguable. If your doctor ignores this text, perhaps it's a sign for you to find a new one.
"This invention relates to a newly discovered reduction in levels of coenzyme Q.sub.10 in human subjects which is a side effect from the administration of MEVACOR (lovastatin). The reduction of tissue levels of
coenzyme Q.sub.10 by oral MEVACOR can in turn cause an increase in cardiac dysfunction, and for patients with advanced cardiac disease, this added dysfunction can be life-threatening. Also, a reduction in levels of
CoQ.sub.10 in human subjects by MEVACOR can depress other essential functions in the human body such as the immune function which can also be very clinically serious and even life-threatening, particularly for any
cancer patient."
"The present invention comprises the heretofore overlooked and very serious side effect of MEVACOR to depress body levels of coenzyme Q.sub.10 and to depress correspondingly cardiac function or the pumping of blood by the heart throughout the body, and the circumvention of this death-threatening side effect by the clinical administration of a formulation of coenzyme Q.sub.10 either (1) concomitantly with MEVACOR or (2) by independent formulations of MEVACOR and coenzyme Q.sub.10 by an appropriate dosage schedule for MEVACOR and coenzyme Q.sub.10 (CoQ.sub.10)."
"The depressed cardiac function which can be caused by MEVACOR is associated with the discovered reduction in blood levels of coenzyme Q.sub.10 (CoQ.sub.10) during the clinical administration of MEVACOR."
"CoQ.sub.10 is a redox coenzyme of the respiratory chain including mechanisms of oxidative phosphorylation. These mechanisms have been known as "bioenergetics" and support life functions including the cardiac function or the pumping of blood by the heart. CoQ.sub.10 is a coenzyme for the mitochondrial enzymes: NADH:CoQ.sub.10 reductase, succinate:CoQ.sub.10 reductase, electron transfer flavoprotein:CoQ.sub.10 reductase, reduced CoQ.sub.10 : cytochrome C reductase. The energy coupling roles of CoQ.sub.10, and the apparent antioxidant activity of CoQ.sub.10, are the specific reactions which are important to maintain metabolic functions of organs such as cardiac function. Any pharmacological treatment, any drug treatment such as the clinical administration of MEVACOR to reduce hypercholesterolemia which reduces blood levels of CoQ.sub.10 and thereby reduces the energy-coupling and other roles of CoQ.sub.10 can be clinically detrimental such as to cardiac function and even life itself."